Acquisition of Technology - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended			1 Months Ended	9 Months Ended		9 Months Ended
	Jun. 30, 2007	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Mallinckrodt [Member] Patents [Member]	May 31, 2014 Development Target One [Member] Questcor [Member] Patents [Member]	Sep. 30, 2014 Development Target One [Member] Questcor [Member] Patents [Member]	Sep. 30, 2014 Development Target One, Two and Three [Member] Mallinckrodt [Member] Patents [Member]	Sep. 30, 2014 Development Target Two [Member] Mallinckrodt [Member] Patents [Member]	Sep. 30, 2014 Development Target Three [Member] Mallinckrodt [Member] Patents [Member]	Sep. 30, 2014 Development Target Four [Member] Mallinckrodt [Member] Patents [Member]
Business Acquisition, Contingent Consideration [Line Items]
Payment expensed as in-process research and development	$ 650,000
General research and development expense		3,088,373	78,731	7,815,466	320,558		500,000
Development targets description								Upon the initiation of the first patient dosing in its Phase 3 clinical trial for EVK-001		Upon the FDA’s acceptance for review of a new drug application for EVK-001	Upon the FDA’s approval of EVK-001	Depend on EVK-001’s commercial success and will only apply if EVK-001 receives regulatory approval. In addition, the Company will be required to pay Mallinckrodt a low single digit royalty on net sales of EVK-001.
Milestone payments						51,500,000
Milestone payments, pegged to development targets									$ 4,500,000	$ 1,500,000	$ 3,000,000	$ 47,000,000
Expected expiration of patent right												2030